

Global Expert Meeting

“Race Against Resistance - What Will Happen When Drug Resistance Spreads?”

Overview

Antimicrobial Resistance (AMR) is causing widespread disruption, with approximately 1.27 million estimated annual deaths directly linked to AMR, as a British medical journal reported in 2022. AMR has been called a “silent pandemic” and “The next threat after COVID-19.” The lack of progress in developing new antimicrobials has revealed the necessity of international cooperation and the importance of pursuing a One Health approach among G7 members and the global community. It should be noted that countries acting alone cannot fully implement infectious disease control and that each country’s interests are adjacent to those of the rest of the world. Looking to the UN High-Level Meeting in 2024, discussions will center on determining the direction and specific measures required, involving stakeholders from government, industry, academia, and civil society. The focus will be on identifying the antibiotic research and development innovation engine. Additionally, assessments of Japan’s leadership within the G7 and the unveiling of forthcoming AMR response plans will be presented.

- **Date & Time:** Tuesday, April 23, 2024, from 18:00 to 20:00 JST
- **Venue:** Global Business Hub Tokyo (100-0004, 1 Chome-9-2 Otemachi, Chiyoda City, Tokyo)
In-person attendance only; no online participation is available
- **Language:** Japanese and English, with simultaneous interpretation
- **Program** (titles omitted; in no particular order):

- | | |
|---------------|--|
| 18:00 - 18:10 | <p>Opening Remarks
 Yasuhisa Shiozaki (Member of the Global Leaders Group on Antimicrobial Resistance/ Former Minister of Health, Labour and Welfare, Japan)
 Drew Ferguson (The United States House of Representative)</p> |
| 18:10 - 18:20 | <p>Explanatory Introduction
 Ryoji Noritake (CEO, Board Member, Health and Global Policy Institute (HGPI))
 Yui Kohno (Manager, Health and Global Policy Institute (HGPI))</p> |
| 18:20 - 19:50 | <p>Discussion “Race Against Resistance - What Will Happen When Drug Resistance Spreads?”
 (All speakers and attendees at the venue)
 Designated Remarks:
 Norio Ohmagari (Director, AMR Clinical Reference Center, National Center for Global Health and Medicine (NCGM))
 Keiji Okinaka (Chief, Division of Infectious Diseases (ID) and Infection Control and Prevention section, National Cancer Center Hospital East (NCCHE) / Staff, Division of Hematopoietic Stem Cell Transplantation (HSCT), National Cancer Center Hospital (NCCH))
 Jun Sugihara (Principal Deputy Director / Director, Office of Ending AIDS Epidemic and Director, Office of Tuberculosis Elimination, Division of Infectious Disease Prevention and Control, Department of Infectious Disease Prevention and Control, Public Health Bureau, Ministry of Health, Labour and Welfare)
 Takuko Sawada (Director and Vice Chairperson of the Board, Shionogi & Co., Ltd)
 Henry Skinner (CEO, AMR Action Fund)</p> |
| 19:50 - 20:00 | <p>Closing</p> |




Speakers Bio (titles omitted; in no particular order)

Norio Ohmagari (Director, Disease Control and Prevention Center (DCC) of National Center for Global Health and Medicine (NCGM) / Director, AMR Clinical Reference Center / Director WHO Collaborating Center for Prevention, Preparedness and Response to Emerging Infectious Diseases)



Dr. Ohmagari has completed his clinical fellowship in Infectious Diseases at University of Texas-Houston. After serving as chief of the Division of Infectious Diseases at the Shizuoka Cancer Center, in 2011 Dr. Ohmagari moved to National Center for Global Health and Medicine (NCGM) which is one of six national medical centers in Japan with infectious diseases as main objective. At NCGM, Dr. Ohmagari has been acting as Director of the Disease Control and Prevention Center since 2012. In April 2017, he started a dual appointment as the Director of the AMR Clinical Reference Center and Director for the WHO Collaborating Centre for Prevention, Preparedness and Response to Emerging Infectious Diseases. From November 2023, he became the Deputy Director for Infection and Crisis Management and from April 2024 holds a dual appointment at as Deputy Director for Disaster and First Aid.

Keiji Okinaka (Chief, Division of Infectious Diseases (ID) and Infection Control and Prevention section, National Cancer Center Hospital East (NCCHE) / Staff, Division of Hematopoietic Stem Cell Transplantation (HSCT), National Cancer Center Hospital (NCCH))



Keiji Okinaka graduated from Hamamatsu University School of Medicine in 2000 before becoming a senior resident in the Division of Infectious Diseases at Shizuoka Cancer Center Hospital between 2008 and 2011. He was also a senior resident in the Department of Hematopoietic Stem Cell Transplantation at the National Cancer Center Hospital in 2011. At the same hospital, between 2011 and 2015, he was a staff member in both the Division of General Internal Medicine (GIM-ID) and Department of Hematopoietic Stem Cell Transplantation (HSCT). From 2015 to 2021 he acted as a staff member in the Division of GIM-ID and a Chief of the Infection Control and Prevention section at the National Cancer Center Hospital East, and since 2022 he has been also be Chief of the Division of Infectious Disease.

Takuko Sawada (Director and Vice Chairperson of the Board, Shionogi & Co., Ltd.)



Following her graduation from Kyoto University, Ms. Takuko Sawada joined Shionogi & Co., Ltd. In 1977. Since then, she has served for over 30 years, leading a number of pharmaceutical development projects and corporate strategy planning. Ms. Sawada successively held various posts in the company including the senior vice president of Global Pharmaceutical Development Division, the senior vice president of Corporate Strategy Division and Corporate Planning Department, and board director. She has served in her current position since 2022

Yasuhisa Shiozaki (Member of the Global Leaders Group on Antimicrobial Resistance/ Former Minister of Health, Labour and Welfare, Japan)



A 1975 graduate of the University of Tokyo, he first joined The Bank of Japan and completed the MPA at the John F. Kennedy School of Government, at Harvard University (1982). First elected to the House of Representatives in 1993, he then ran for the House of Councillors in 1995, and was re-elected to the House of Representatives in 2000, where he served eight terms. After having served as Chief Cabinet Secretary, Minister of State for the Abduction Issue and Senior Vice-Minister for Foreign Affairs, he was appointed as Minister of Health, Labour and Welfare in 2014 and held this position until August 2017.

Henry Skinner (CEO, AMR Action Fund)



Dr. Henry Skinner is the Chief Executive Officer of the AMR Action Fund, with nearly \$1 billion USD under management to invest in companies worldwide that are developing antimicrobials for priority pathogens and advocate for market reforms to change how society values these lifesaving drugs. Prior to joining the Fund, Dr. Skinner held leadership positions across the pharmaceutical and venture capital sectors, including serving as Senior Vice President, Venture, at Tekla Capital Management and as Deputy Head and Managing Director of the Novartis Venture Fund. In addition, he was the CEO of SelectX Pharmaceuticals, which focused on developing small-molecule antimicrobials, and NeoGenesis Pharmaceuticals, which developed a platform for identifying and optimizing drug candidates. He was a postdoctoral fellow at Baylor College of Medicine in the department of Human and Molecular Genetics, and he earned a PhD in Microbiology and an MS in Biochemistry from the University of Illinois.

Jun Sugihara (Principal Deputy Director / Director, Office of Ending AIDS Epidemic and Director, Office of Tuberculosis Elimination, Division of Infectious Disease Prevention and Control, Department of Infectious Disease Prevention and Control, Public Health Bureau, Ministry of Health, Labour and Welfare)



Dr. Jun Sugihara is a medical officer at the Ministry of Health, Labour and Welfare (MHLW), Japan. Dr. Sugihara currently serves as the Principal Deputy Director of Infectious Disease Prevention and Control Division and co-assigned as the Director of the Office of Ending AIDS Epidemic/Office of Tuberculosis Elimination. He also serves as the Deputy Chief of the Strategic Planning Task Force within MHLW's COVID-19 Response Headquarters. Prior to his current position, he worked as a Global Health Security Coordinator and a technical lead for the International Health Regulations National Focal Point of Japan at MHLW from 2018 to 2021. Dr. Sugihara was deployed to the U.S. Centers for Disease Control and Prevention and the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services as a liaison to coordinate bilateral health security issues from 2016 to 2018. Before joining MHLW, he worked as a clinician specialized in infectious disease at the National Center for Global Health and Medicine in Japan and a consultant of the World Health Organization Western Pacific Regional Office. Dr. Sugihara received his medical degree from Yokohama City University, Master of Public Health from Johns Hopkins Bloomberg School of Public Health and the Postgraduate Diploma in Tropical Medicine and Hygiene from London School of Hygiene and Tropical Medicine. He is an Infectious Disease Emergency Management Specialist certified by MHLW.

Drew Ferguson (The United States House of Representative)



Congressman Drew Ferguson is a Republican member of the U.S. House of Representatives. His tenure representing the State of Georgia's 3rd Congressional District began on 3 January 2017. He is a longtime champion of efforts to battle drug-resistant infections, and in December 2020 introduced the bipartisan, bicameral Pioneering Antimicrobial Subscription To End Upsurging Resistance (PASTEUR) Act, which encourages innovative drug development targeting the most threatening infections, improves the appropriate use of antibiotics, and ensures domestic availability of antibiotics when needed. He reintroduced the bill, which establishes a fully delinked subscription model with contracts that could be valued between \$750 million and \$3 billion USD, in April 2023. Rep. Ferguson sits on the House Committee on Budget and the Committee on Ways and Means. Previously, Rep. Ferguson spent eight years as mayor of West Point, Georgia. He graduated from the University of Georgia and received a degree in dental medicine from the Medical College of Georgia.

Ryoji Noritake (CEO, Board Member, Health and Global Policy Institute)



Mr. Ryoji Noritake is the CEO, and Board Member of Health and Global Policy Institute (HGPI), a Tokyo-based independent and non-profit health policy think tank established in 2004. He also served as Asia-Pacific Lead for Project HOPE, a US-based medical humanitarian aid organization. Through HOPE and HGPI, he has led health system strengthening projects in the Asia-Pacific region and engaged in the US Navy's medical humanitarian projects. His focus is a multi-sectoral approach to health issues such as public-private partnerships and civil-military coordination. He was a member of the Tokyo Metropolitan Government's Policy Discussion Roundtable for Super Ageing Society (2018) and served as a Visiting Scholar at the National Graduate Institute for Policy Studies (2016-2020). He is currently serving as a member of World Dementia Council (WDC), the Salzburg Global Seminar's Advisory Council, Advisory Board Member of Elsevier Atlas, and the Dementia Innovation Alliance hosted by the Ministry of Economy, Trade and Industry (METI), Japan. He was awarded the 32th Takemi Incentive Award in 2022. He is a graduate of Keio University's Faculty of Policy Management and holds a MSc in Medical Anthropology from the University of Amsterdam, the Netherlands.

Yui Kohno (Manager, Health and Global Policy Institute)



Ms. Yui Kohno is a graduate of the University of Sydney School of Public Health's Faculty of Medicine and Health in Australia. After obtaining a Master of Health Policy degree from the University of Sydney, Ms. Kohno joined Health and Global Policy Institute. There, she is responsible for research and analysis of national and global policy challenges within and beyond the fields of Antimicrobial Resistance (AMR) and vaccination. Her activities include planning and coordinating conferences for better policy dialogue and discussion and engaging in public relations, outreach, and advocacy activities.



About Health and Global Policy Institute (HGPI)

Health and Global Policy Institute (HGPI) is a non-profit, independent, non-partisan health policy think tank established in 2004. As a neutral think-tank, HGPI involves stakeholders from wide-ranging fields of expertise to provide policy options to the public to create citizen-focused healthcare policies successfully. Looking to the future, HGPI produces novel ideas and values from a comprehensive perspective. It aims to realize a healthy and fair society while holding fast to its independence to avoid being bound to the specific interests of political parties and other organizations. HGPI intends for its policy options to be effective in Japan and the broader world. In this vein, the institute will continue to actively create policies for resolving global health challenges. HGPI's activities have received international recognition. It was ranked second in the "Domestic Health Policy Think Tanks" category and third in the "Global Health Policy Think Tanks" category in the Global Go To Think Tank Index Report presented by the University of Pennsylvania (as of January 2021, the most recent report).

About AMR Alliance Japan

AMR Alliance Japan is an independent platform for the promotion of multisector discussion on AMR countermeasures. Since its establishment in November 2018, AMR Alliance Japan has worked with Alliance members and partner organizations to deepen policy debate around AMR. Current Members (as of April, 2024) are bioMérieux Japan Ltd., GlaxoSmithKline K.K., Himeji City, Japan Medical Association, Japan Pharmaceutical Association, Japan Pharmaceutical Manufacturers Association, Japanese Association of Medical Technologists, Japanese Society for Pediatric Infectious Diseases, Japanese Society of Antimicrobials for Animals, Japanese Society of Chemotherapy, Japanese Society of Hospital Pharmacists, "Kodomo to Iryo" Project, Meiji Seika Pharma Co., Ltd., MSD K.K., Nippon Becton, Dickinson and Company, Ltd., Pfizer Japan Inc., Shimadzu Diagnostics Corporation, Shionogi & Co., Ltd., Sumitomo-Pharma Co., Ltd., The Japanese Society for Medical Mycology, The Japanese Association for Infectious Diseases, The Japanese Society for Clinical Microbiology, The Japanese Society for Infection Prevention and Control, The Japanese Society of Pharmaceutical Health Care and Sciences, The Japanese Society of Therapeutic Drug Monitoring, The Pharmaceutical Society of Japan, Health and Global Policy Institute (HGPI) serves as Secretariat of the Alliance.

Health and Global Policy Institute: Guidelines on Grants and Contributions

As an independent, non-profit, non-partisan private think tank, HGPI complies with the following guidelines relating to the receipt of grants and contributions.

1. Approval of Mission

The mission of HGPI is to improve the civic mind and individuals' well-being, and to foster a sustainable healthy community by shaping ideas and values, reaching out to global needs, and catalyzing society for impact. The activities of the Institute are supported by organizations and individuals who are in agreement with this mission.

2. Political Neutrality

HGPI is a private, non-profit corporation independent of the government. Moreover, we receive no support from any political party or other organization whose primary purpose is political activity of any nature.

3. Independence of Project Planning and Implementation

HGPI makes independent decisions on the course and content of its projects after gathering the opinions of a broad diversity of interested parties. The opinions of benefactors are solicited, but the Institute exercises independent judgment in determining whether any such opinions are reflected in its activities.

4. Diverse Sources of Funding

In order to secure its independence and neutrality, HGPI will seek to procure the funding necessary for its operation from a broad diversity of foundations, corporations, individuals, and other such sources. Moreover, as a general rule, funding for specific divisions and activities of the Institute will also be sought from multiple sources.

5. Exclusion of Promotional Activity

HGPI will not partake in any activity of which the primary objective is to promote or raise the image or awareness of the products, services or other such like of its benefactors.

6. Written Agreement

Submission of this document will be taken to represent the benefactor's written agreement with HGPI's compliance with the above guidelines.

